A low ALKBH1 protein level is associated with more advanced TNM stages and larger tumor volume, and low FTO expression is correlated with shorter OS in GC patients.[158] Another study also proved that FTO overexpression is an independently valid predictor of prognosis and survival in GC patients.[157] The expression of the m6A reader YTHDF3 correlates with tumor stage, and YTHDC2 correlates with the survival of GC patients.[155] Wang et al. found that IGF2BP1 single-nucleotide polymorphism is correlated with the risk of discovery stage in GC. This evidence concerns the gene YTHDC2 and neoplasm.